Cargando…

Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?

Immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder featured by increased platelet destruction and deficient megakaryocyte maturation. First-line treatments include corticosteroids, intravenous immunoglobulin and intravenous anti-D immunoglobulin. Second-line treatments consist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lv, Yue, Shi, Huiping, Liu, Hong, Zhou, Lu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393521/ https://www.ncbi.nlm.nih.gov/pubmed/36003388 http://dx.doi.org/10.3389/fimmu.2022.953716

Ejemplares similares

Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives
por: Vianelli, Nicola, et al.
Publicado: (2022)

Rituximab resistance in ITP and beyond
por: Xiao, Zhengrui, et al.
Publicado: (2023)

Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
por: Marshall, Michael J. E., et al.
Publicado: (2017)

What We Have Learned and What We Have Missed in Tuberculosis Pathophysiology for a New Vaccine Design: Searching for the “Pink Swan”
por: Cardona, Pere-Joan
Publicado: (2017)

Steroid-Refractory Gut Graft-Versus-Host Disease: What We Have Learned From Basic Immunology and Experimental Mouse Model
por: Song, Qingxiao, et al.
Publicado: (2022)

Refractory chronic “ITP”: When platelet size matters
por: Baliakas, Panagiotis, et al.
Publicado: (2018)

Assessment and Management of Immune Thrombocytopenia (ITP) in the Emergency Department: Current Perspectives
por: Zitek, Tony, et al.
Publicado: (2022)

Recent advances in pruritus - what we have learned and where are we headed
por: Yosipovitch, Gil
Publicado: (2010)

Long non‐coding RNAs regulate treatment outcome in leukemia: What have we learnt recently?
por: Shi, Huiping, et al.
Publicado: (2023)

Emerging Biomarkers and Therapeutic Strategies for Refractory Bullous Pemphigoid
por: Zhou, Tong, et al.
Publicado: (2021)

Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma
por: Du, Mengyi, et al.
Publicado: (2022)

What Have We Learnt about BCG Vaccination in the Last 20 Years?
por: Dockrell, Hazel M., et al.
Publicado: (2017)

Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)
por: Zufferey, Anne, et al.
Publicado: (2017)

Extreme Thrombocytosis in Refractory ITP Post-Splenectomy With Associated Fatal Thromboembolism
por: Nedumannil, Rithin, et al.
Publicado: (2022)

Narcolepsy and H1N1 influenza immunology a decade later: What have we learned?
por: Buonocore, Sofia M., et al.
Publicado: (2022)

An ITP workbook
por: Kalman, J A
Publicado: (1986)

Immunoglobulin M in Health and Diseases: How Far Have We Come and What Next?
por: Jones, Katelyn, et al.
Publicado: (2020)

COVID-19 isolation strategies: What have we learned
por: Al-Tawfiq, Jaffar A., et al.
Publicado: (2022)

Immune Thrombocytopenia (ITP): Current Limitations in Patient Management
por: Terrell, Deirdra R., et al.
Publicado: (2020)

Pemphigus: Current and Future Therapeutic Strategies
por: Didona, Dario, et al.
Publicado: (2019)

What have we learned?
por: Rodgers, Peter, et al.
Publicado: (2021)

Anesthesia and developing brain: What have we learned from recent studies
por: Niu, Yixuan, et al.
Publicado: (2022)

Cellular and Molecular Mechanisms of Anterior Chamber-Associated Immune Deviation (ACAID): What We Have Learned from Knockout Mice
por: Vendomèle, Julie, et al.
Publicado: (2017)

Innate immunity and chronic rhinosinusitis: What we have learned from animal models
por: London, Nyall R., et al.
Publicado: (2016)

ITP Conference on High T
por: Collective
Publicado: (2000)

Lenalidomide-Associated ITP
por: Herold, Christina I., et al.
Publicado: (2011)

Neutrinos, what we have learned about them and what we have learned using them
por: Steinberger, J
Publicado: (2013)

Psychological Interventions for Dementia Caregivers: What We Have Achieved, What We Have Learned
por: Cheng, Sheung-Tak, et al.
Publicado: (2019)

Extracellular vesicles as advanced therapeutics for the resolution of organ fibrosis: Current progress and future perspectives
por: Lv, Ke, et al.
Publicado: (2022)

Therapeutic Use of the Ketogenic Diet in Refractory Epilepsy: What We Know and What Still Needs to Be Learned
por: Zarnowska, Iwona Maria
Publicado: (2020)

GOAL: What Have We Learned?
por: Leek, Timothy K Vander
Publicado: (2005)

What have we learned on mesons?
por: Moebes, J P
Publicado: (1972)

SARS: What have we learned?
Publicado: (2003)

Integrin-α9β1 as a Novel Therapeutic Target for Refractory Diseases: Recent Progress and Insights
por: Xu, Shihan, et al.
Publicado: (2021)

SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP
por: Lee, Eun-Ju, et al.
Publicado: (2022)

The dsDNA, Anti-dsDNA Antibody, and Lupus Nephritis: What We Agree on, What Must Be Done, and What the Best Strategy Forward Could Be
por: Rekvig, Ole Petter
Publicado: (2019)

PB2619: THE IMPACT OF ITP-DIRECTED TREATMENT ON FATIGUE AMONG CHILDREN AND ADOLESCENTS WITH CHRONIC ITP: DATA FROM THE ITP NATURAL HISTORY STUDY REGISTRY
por: Diraimo, Jennifer, et al.
Publicado: (2023)

PTH Assays: Understanding What We Have and Forecasting What We Will Have
por: Vieira, Jose Gilberto H.
Publicado: (2012)

Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment—Current Progress, Strategy, and Future Perspective
por: Guo, Libin, et al.
Publicado: (2020)

Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives
por: Guo, Zong Sheng, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jgmoifm49bnqtcm9pu1d3qbc9e